Immune atlas of pituitary neuroendocrine tumors highlights endocrine-driven immune signature and therapeutic implication
Open Access
- 16 April 2025
- journal article
- Published by Elsevier in Cell Reports
- Vol. 44 (5) , 115584
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82203527)
- Natural Science Foundation of Beijing Municipality (7232105)
This publication has 64 references indexed in Scilit:
- Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumorsCancer Letters, 2024
- Polysaccharides regulate Th1/Th2 balance: A new strategy for tumor immunotherapyBiomedicine & Pharmacotherapy, 2023
- Diagnosis and Management of Pituitary AdenomasJAMA, 2023
- CD38: An important regulator of T cell functionBiomedicine & Pharmacotherapy, 2022
- Overview of the 2022 WHO Classification of Pituitary TumorsEndocrine Pathology, 2022
- In silico analysis of the immunological landscape of pituitary adenomasJournal of Neuro-Oncology, 2020
- Immunedeconv: An R Package for Unified Access to Computational Methods for Estimating Immune Cell Fractions from Bulk RNA-Sequencing Data2020
- Automated Data Cleanup for Mass CytometryCytometry Part A, 2019
- Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone AdenomasEndocrine Pathology, 2015
- A regulatory role of prolactin, growth hormone, and corticosteroids for human T-cell production of cytokinesBrain, Behavior, and Immunity, 2004